Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.50 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | GGT1 | P19440 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21690060 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL10212363 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL21577850 | 0.86 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL434919 | 0.85 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL21585639 | 0.85 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL380601 | 0.85 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL434918 | 0.85 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL21585654 | 0.83 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL18261645 | 0.81 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL12368601 | 0.80 | ALDH1A1 (0.36) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112135812-B | Ketamine derivatives and pharmaceutical compositions thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-01-18 | — | — | CN | claimed |
| EP-3710458-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12312370-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-111491938-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11649215-B2 | Compositions and methods for the treatment of oral infectious diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2023-05-16 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11465973-B2 | Compositions and methods for the treatment of oral infectious diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2022-10-11 | — | — | US | disclosed |
| US-20220220079-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-14 | — | — | US | disclosed |
| US-11000487-B2 | Compositions and methods for the treatment of chronic pain | CELLIX BIO PRIVATE LIMITED (IN) | 2021-05-11 | — | — | US | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20210053950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2021-02-25 | — | — | US | disclosed |
| US-20210032194-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2021-02-04 | — | — | US | disclosed |
| US-20200361874-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2020-11-19 | — | — | US | disclosed |
| US-20200361912-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2020-11-19 | — | — | US | disclosed |
| EP-3710458-A1 | IMMUNOPROTEASOME INHIBITORS | Principia Biopharma Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
| CN-111491938-A | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190350877-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN | CELLIX BIO PRIVATE LIMITED (IN) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | SLC7A5 3751/4885SLC1A3 4197/4885SLC1A2 4190/4885 |
| US-20220220079-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | SI, HBG1, HBG2 | SLC7A5 1984/4885SLC1A3 3752/4885SLC1A2 3415/4885 |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | SLC7A5 3751/4885SLC1A3 4197/4885SLC1A2 4190/4885 |
| US-20190350877-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN | OPRK1, F5, F12 | SLC7A5 2865/4885SLC1A3 2689/4885SLC1A2 2001/4885 |
| US-11649215-B2 | Compositions and methods for the treatment of oral infectious diseases | SI, HBG1, HBG2 | SLC7A5 1984/4885SLC1A3 3752/4885SLC1A2 3415/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | SLC7A5 2832/4885SLC1A3 4504/4885SLC1A2 4689/4885 |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | SLC7A5 3751/4885SLC1A3 4197/4885SLC1A2 4190/4885 |
| US-11465973-B2 | Compositions and methods for the treatment of oral infectious diseases | SI, HBG1, HBG2 | SLC7A5 1984/4885SLC1A3 3752/4885SLC1A2 3415/4885 |
| US-12312370-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | SLC7A5 3751/4885SLC1A3 4197/4885SLC1A2 4190/4885 |
| US-20210053950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | SI, CYP3A7, ERG28 | SLC7A5 2338/4885SLC1A3 3715/4885SLC1A2 3574/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | SLC7A5 2832/4885SLC1A3 4504/4885SLC1A2 4689/4885 |
| US-20200361874-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | SI, HBG1, HBG2 | SLC7A5 1984/4885SLC1A3 3752/4885SLC1A2 3415/4885 |
| US-20210032194-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | SCNN1G, PMP22, TTR | SLC7A5 1437/4885SLC1A3 486/4885SLC1A2 172/4885 |
| US-20200361912-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | SI, CYP3A7, ERG28 | SLC7A5 2338/4885SLC1A3 3715/4885SLC1A2 3574/4885 |
| US-11000487-B2 | Compositions and methods for the treatment of chronic pain | OPRK1, F5, F12 | SLC7A5 2865/4885SLC1A3 2689/4885SLC1A2 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.